<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83085">
  <stage>Registered</stage>
  <submitdate>20/08/2008</submitdate>
  <approvaldate>8/09/2008</approvaldate>
  <actrnumber>ACTRN12608000447358</actrnumber>
  <trial_identification>
    <studytitle>Pravastatin in Polycystic Kidney Disease</studytitle>
    <scientifictitle>Effect of Pravastatin on Kidney Function in Polycystic Kidney Disease</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Polycystic Kidney Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Pravastatin 20mg orally daily for 2 years</interventions>
    <comparator>Control group with no treatment</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Serum Creatinine (blood analysis)</outcome>
      <timepoint>every 3 months for 2 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Proteinuria measured by 24 hour urine collection</outcome>
      <timepoint>every 3 months for 2 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Polycystic kidney disease</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>85</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Females of Child bearing potential</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Patients screened and identified as having polycystic kidney disease attending the nephrologists clinics offered enrollment 
Independent central co-ordinator performs randomization from computer generated random numbers placed in concealed envelopes</concealment>
    <sequence>Computer generated random numbers</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3 / Phase 4</phase>
    <anticipatedstartdate>1/01/1998</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Charities/Societies/Foundations</primarysponsortype>
    <primarysponsorname>Clifford Craig Medical Research Trust</primarysponsorname>
    <primarysponsoraddress>Launceston General Hospital
Charles St, Launceston, 7250</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Clifford Craig Medical Research Trust</fundingname>
      <fundingaddress>Launceston General Hospital
Charles St, Launceston, 7250</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Polycystic kidney disease is a common cause of kidney failure
Statins may slow kidney disease progression.
This study aimed to assess whether pravastatin 20mg could slow the progression of kidney disease</summary>
    <trialwebsite>Nil</trialwebsite>
    <publication>Nil</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Epworth Research and Ethics Committee</ethicname>
      <ethicaddress>Epworth Medical Centre
185-187 Hoddle Street
Richmond, VIV, 3121</ethicaddress>
      <ethicapprovaldate>11/02/1997</ethicapprovaldate>
      <hrec>9096S</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor Robert Fassett</name>
      <address>Renal Research Tasmania
Launceston
Charles Street
Launceston Tasmania</address>
      <phone>0419399571</phone>
      <fax>0363487577</fax>
      <email>rfassett@mac.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Professor Robert Fassett</name>
      <address>Renal Research Tasmania
Launceston General Hospital
Charles Street
Launceston
Tasmania</address>
      <phone>0419399571</phone>
      <fax>0363487577</fax>
      <email>rfassett@mac.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Professor Robert Fassett</name>
      <address>Renal Research Tasmania
Launceston General Hospital
Charles Street
Launceston 
Tasmania</address>
      <phone>0419399571</phone>
      <fax>0363487577</fax>
      <email>rfassett@mac.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>